Multi-4SCAR-T Therapy Targeting Breast Cancer

  • End date
    Dec 31, 2023
  • participants needed
  • sponsor
    Shenzhen Geno-Immune Medical Institute
Updated on 24 January 2021


The purpose of this study is to assess the feasibility, safety and efficacy of multiple 4th generation CAR-T cells targeting Her2, GD2, and CD44v6 surface antigen in breast cancer. Another goal of the study is to learn more about the activities of the multi-CAR T cells and their persistency in the patients.


Breast cancer is one of the most frequent cancer types in women. The average risk of a woman in the United States developing breast cancer in her life is about 13%. That means that there is a 1 in 8 chance she will develop breast cancer. Human epidermal growth factor receptor-2 (HER2) is one of the more well-researched genes in breast cancer so far. It has been reported that HER2 gene is overexpressed in 20% to 30% of breast cancer patients. HER2 is an important target for tumor gene therapy. In 2003, scientists confirmed the existence of breast cancer stem cells. In 2012, ganglioside GD2 was confirmed as an emerging marker of breast cancer stem cells. Targeting therapies for GD2 may help improve the survival rate and cure rate of breast cancer patients. Invasion and metastasis of tumor cells is the main cause of cancer death. CD44v6 is an adhesion molecule on the cell surface, which not only promotes epithelial-mesenchymal transition, degradation and remodeling of extracellular matrix, but also participates in organ-specific metastasis of tumor cells. Studies have shown that overexpression of CD44v6 is an important factor for the invasion and metastasis of breast cancer, and is closely related to the tumor size of the breast cancer, tumor staging, and lymph node metastasis. Therefore, CD44v6 may be an important target for the treatment of breast cancer. Using Her2-, GD2- and CD44v6-specific CAR-T cells may effectively improve the immunotherapy treatment, prevent tumor cells from escaping treatment, and achieve the effect of long-term disease relief.

Condition Breast Cancer, Breast Cancer, Breast Cancer Diagnosis, breast carcinoma, cancer, breast
Treatment 4SCAR T cells
Clinical Study IdentifierNCT04430595
SponsorShenzhen Geno-Immune Medical Institute
Last Modified on24 January 2021


Yes No Not Sure

Inclusion Criteria

Patients with stage III, IV or relapsed breast cancer confirmed by histology and biopsy
Age: 18 years and 75 years
2 weeks at least since last chemotherapy or radiotherapy and 2 weeks at least since last systemic steroid hormone and other immunosuppressive therapy
Side effects of chemotherapy have subsided
The target antigens GD2, CD44v6, or Her2 is expressed in malignancy tissues by immuno-histochemical or flow cytometry
Eastern Cooperative Oncology Group (ECOG) PS of 0 or 1
Expected survival 12 weeks
Initial hematopoietic reconstitution with neutrophils (ANC) 110^6/L; platelet (PLT) 110^8/L
Proper renal and hepatic functions (ULN denotes "upper limit of normal range") with serum creatinine 2ULN; serum bilirubin 3ULN; AST/ALT 2.5ULN
Oxygen saturation 90%
Written, informed consent obtained prior to any study-specific procedures

Exclusion Criteria

Airway obstruction caused by tumor
History of epilepsy or other central nervous system diseases
Patients who require systemic corticosteroid or other immunosuppressive therapy
History of prolonged or serious heart disease during QT
Current or recent treatment (within the 28-day period prior to Day 0) with another investigational drug or previous participation in this study
Inadequate liver and renal function with serum creatinine > 1.5 mg/dl; serum (total) bilirubin > 2.0 mg/dl; AST & ALT > 3 x ULN
Pregnant or lactating females
Serious active infection during screening
Active HIV, hepatitis B virus (HBV), hepatitis C virus (HCV) infection or uncontrolled infection
Patients, in the opinion of investigators, may not be eligible or not able to comply with the study
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact



Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note